Alnylam Pharmaceuticals Inc.
Alnylam Announces New Five-Year Strategy and Preliminary 2025 Financial Results
Summary
Alnylam Pharmaceuticals, Inc. announced its new five-year strategy, 'Alnylam 2030', and reported preliminary full year 2025 global net product revenues of approximately $2.987 billion, with an 81% growth compared to 2024. The company also provided 2026 combined net product revenue guidance of $4.900 billion to $5.300 billion, with an expected 71% growth from 2025. The new strategy aims for global leadership in TTR, sustainable innovation, and disciplined growth to achieve a 25%+ total revenue CAGR through 2030.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement